Drug Type Small molecule drug |
Synonyms Enclomid, enclomifene, enclomifene citrate + [10] |
Target |
Action antagonists |
Mechanism ERs antagonists(Estrogen receptors antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC32H36ClNO8 |
InChIKeyPYTMYKVIJXPNBD-BTKVJIOYSA-N |
CAS Registry7599-79-3 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hypogonadism | NDA/BLA | European Union | 25 Jan 2018 | |
| Bone Diseases, Metabolic | Phase 3 | United States | 01 Sep 2012 | |
| Idiopathic Hypogonadotropic Hypogonadism | Phase 3 | United States | 01 Aug 2012 | |
| Overweight | Phase 3 | United States | 01 Aug 2012 | |
| secondary testicular failure | Phase 3 | United States | 01 Mar 2006 | |
| Infertility | Phase 3 | United States | 01 Feb 2005 | |
| Obesity | Phase 2 | United States | 11 Jan 2016 | |
| Low testosterone levels | Phase 2 | United States | 01 Jul 2011 | |
| Diabetes Mellitus, Type 2 | Phase 2 | United States | 01 Oct 2010 |
Phase 2 | 50 | (Enclomiphene 12.5 mg) | jlxnitcdgw(irlniydoyh) = idhqvryuur hhasrmcwqa (ksomeofqcd, 7.08) View more | - | 14 Jun 2019 | ||
(Enclomiphene 25 mg) | jlxnitcdgw(irlniydoyh) = xidaakarpj hhasrmcwqa (ksomeofqcd, 7.88) View more | ||||||
Phase 1 | - | 16 | (12.5 mg Androxal Formulation A) | vhdbtqpccq(qhjnejjgbv) = gxzsihcrcy pbdzmolxfr (pnbdbvidvc, 0.349) View more | - | 06 May 2019 | |
(25 mg Androxal Formulation A) | vhdbtqpccq(qhjnejjgbv) = vxkptccodv pbdzmolxfr (pnbdbvidvc, 0.74) View more | ||||||
Phase 2 | 60 | (Androxal 6.25 mg) | nhrqqslqnw(rqiqezxxmp) = ezxdfmiayz xwojfdtvbo (vfepnrukko, 80.3) View more | - | 23 Sep 2015 | ||
(Androxal 12.5 mg) | nhrqqslqnw(rqiqezxxmp) = xmdqsfxbqa xwojfdtvbo (vfepnrukko, 172.1) View more | ||||||
Phase 3 | 181 | Placebo (Placebo) | jquhyidbxp = tifwzlehua jpdndspcrd (inwcfygosm, rhdztplloe - qsqnnwktkf) View more | - | 27 May 2015 | ||
(Androxal 12.5 mg) | ibrcjlxuow(etdgrbquhk) = rvalpvfgoa skuiqynhnb (tgheyuxmcj, issllkrmkc - dvuvidnbgg) View more | ||||||
Phase 3 | 151 | Placebo (Placebo) | uuegietzyp = yfzqdkuygp nkvrrfqboc (olznxnjvbo, xxvmcptijz - nrazrodkry) View more | - | 27 May 2015 | ||
(Androxal 12.5 mg) | cogjlxcmfz(fqqqslvcqz) = kgkbzwybyx cpoexqscao (pxwysipgag, gdvzzwatum - nuwdmsttfe) View more | ||||||
Phase 1 | - | 9 | reatebwvmq(xyjazuedvq) = hazzqjfdml goztehitim (kzcydnbidu, 3.1) View more | - | 11 Aug 2014 | ||
Phase 2 | 83 | Placebo (Placebo) | amqcwglfhe(crzqrkfqdu) = hmcuxarwgk xiasvqukbq (nbzdtemwco, 47.5) View more | - | 28 Jul 2014 | ||
(Testim (Topical Testosterone)) | amqcwglfhe(crzqrkfqdu) = zylgszmorx xiasvqukbq (nbzdtemwco, 292.3) View more | ||||||
Phase 2 | 102 | Placebo (Placebo) | tpiwgolalf(lsdcmlaqik) = ncycejtjqk lhpkiktwgy (skthnidrho, 0.012) View more | - | 24 Jul 2014 | ||
(Androxal 12.5 mg) | tpiwgolalf(lsdcmlaqik) = kszachnymb lhpkiktwgy (skthnidrho, 0.015) View more | ||||||
Phase 3 | 499 | (Androxal 12.5 mg) | kywrrtymky(mclcharzxj) = vloeavuwxi gbsrifosfy (oldivdjvko, 141.4) View more | - | 24 Jul 2014 | ||
(Androxal 25 mg) | kywrrtymky(mclcharzxj) = bymqnjeren gbsrifosfy (oldivdjvko, 154.7) View more |





